Background: Neuropeptide Y (NPY) is a 36-amino-acid peptide that was originally isolated from the porcine brain. NPY, in contrast to leptin, is one of the most potent appetite stimulants. In some previous studies, NPY was found to be correlated with mean blood pressure (MBP) and fluid volume in patients on hemodialysis (HD), contributing to volume-induced hypertension. However, it is still unclear which NPY-sensitive neuronal pathways are responsible for the various changes seen in response to central NPY administration. In this study we analyzed the correlation of circulating levels of NPY with parameters of nutritional conditions, and we investigated the relationships between NPY concentrations and clinical markers of fluid volume in patients on HD. We also evaluated the effects of high-flux dialysis membranes on plasma NPY levels as compared with those of low-flux membrane. Methods: Plasma NPY concentrations in patients on regular HD were measured using commercially available radioimmunoassay (RIA) kits. We examined the relationship between plasma NPY concentration and other clinical indices in patients on HD. Results: Plasma NPY concentrations were inversely correlated with the serum urea nitrogen levels (r = –0.32) as well as protein catabolic rate (PCR) (r = –0.28). Plasma NPY was also correlated with the increase in body weight between HD sessions (r = 0.29). On the other hand, plasma NPY concentrations were not correlated with MBP, atrial natriuretic peptide (ANP), or adrenomedullin (AM). The reduction rate of plasma NPY with a high-flux dialysis membrane was significantly higher than that with a low-flux dialysis membrane. Conclusions: The secretion of NPY may be enhanced in a poor state of nourishment and stress induced by fluid volume overload in patients on HD, and plasma NPY is removed by a high-flux dialyzer.

1.
Iseki K, Kawazoe N, Fukiyama K: Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 1993;44:115–119.
2.
Nakazono H, Nagake Y, Kumagai I, Ichikawa H, Suga H, Makino H: Relationship between parameters of the urea kinetic model and serum amino acid levels in patients on hemodialysis. Clin Exp Nephrol 1999;3:116–122.
3.
Abizaid A, Walker CD, Woodside B: Changes in neuropeptide Y immunoreactivity in the arcuate nucleus during and after food restriction in lactating rats. Brain Res 1997;761:306–312.
4.
Wilding JP, Ajala MO, Lambart PD, Bloom SR: Addictive effects of lactation and food restriction to increase hypothalamic neuropeptide Y mRNA in rats. J Endocrinol 1997;152:365–369.
5.
Sanacora G, Kershaw M, Finkelstein JA, White JD: Increased hypothalamic content of preproneuropeptide-Y messenger ribonucreic acid in genetically obese Zucker rats and its regulation by food deprivation. Endocrinology 1990;127:730–737.
6.
Larsen PJ, Tang-Christensen M, Stidsen CE, Madsen K, Smith MS, Cameron JL: Activation of central neuropeptide Y Y1 receptors potently stimulates food intake in male rhesus monkeys. J Clin Endocrinol Metab 1999;84:3781–3791.
7.
Bald M, Gerigk M, Rascher W: Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. Am J Kidney Dis 1997;30:23–27.
8.
Odar-Cederlöf I, Ericsson F, Theodorsson E, Kjellstrand CM: Is neuropeptide Y a contributor to volume-induced hypertension? Am J Kidney Dis 1998;31:803–808.
9.
Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M: Radioimmunoassay of leptin in human plasma. Clin Chem 1996;42:942–946.
10.
Jindal KH, Manuel A, Goldstein MB: Percent reduction in blood area concentration during hemodialysis. ASAIO Trans 1987;33:286–288.
11.
Ichikawa H, Nagake Y, Takahashi M, Ogura T, Makino H: Significance of atrial and brain natriuretic peptides in patients with diabetes mellitus undergoing hemodialysis. Clin Exp Nephrol 1997;1:41–50.
12.
Yamasaki H, Nagake Y, Makino H: Plasma adrenomedullin levels in patients on hemodialysis. Nephron, in press.
13.
Schwartz MW, Seeley RJ: Neuroendocrine responses to starvation and weight loss. N Engl J Med 1997;336:1802–1811.
14.
Niimi M, Sato M, Taminato T: Neuropeptide Y in central control and interactions with orexin and leptin. Endocrine 2001;14:269–273.
15.
Kokot F, Wiecek A, Mesjasz J, Adamczak M, Spiechowicz U: Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialyzed uraemic patients. Nephrol Dial Transplant 1998;13:1200–1205.
16.
Hegbrant J, Thysell H, Ekman R: Plasma levels of vasoactive regulatory peptides in patients receiving regular hemodialysis treatment. Scand J Urol Nephrol 1992;26:169–176.
17.
Viidas U, Noree LO, Ahlmen J, Theodorsson E, Sylven C: Ambulatory 24-hour blood pressure and peptide balance in hemodialysis patients. Scand J Urol Nephrol 1995;29:259–263.
18.
Takahashi K, Mouri T, Tachibana Y, Itoi K, Sone M, Nozuki M, Murakami O, Ohneda M, Yoshinaga K: Neuropeptide Y and blood pressure in haemodialysis patients. Endocrinol Jpn 1989;36:553–558.
19.
Hegbrant J, Thysell H, Martensson L, Ekman R, Boberg U: Changes in plasma levels of vasoactive peptides during standard bicarbonate hemodialysis. Nephron 1993;63:303–308.
20.
Hegbrant J, Thysell H, Martensson L, Ekman R, Boberg U: Changes in plasma levels of vasoactive peptides during sequential bicarbonate hemodialysis. Nephron 1993;63:309–313.
21.
Hegbrant J; Martensson L, Thysell H, Ekman R, Boberg U: Changes in plasma levels of vasoactive substance during routine acetate and bicarbonate hemodialysis. Clin Nephrol 1994;41:106–112.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.